Cialis would be number 1 this December
July 13, 2007

Lilly planning educate more people about Erectile dysfunction and its treatments

Erectile Dysfunction is the disease which has become a major problem for most on me in this globe also erectile-dysfunction sell continues to grow steadily, in high single-digit percentages

Cialis has sustained to gain market share every sector since it was launched in 2003, Lilly said. And any continuous improvement in Cialis outcome likely will help the bottom line at Lilly, which bought full control of the drug from associate Icos Corp. for $2.3 billion.

Lilly predicted Cialis sales will peak $1 billion this year, giving it blockbuster status.
According to the company cialis would be number 1 in December outside the U.S. this year, beating out Viagra.

Worldwide sales of Cialis in the first quarter were $265.8 million, up 19 percent from a year earlier. Another thing in Cialis' errand is that the drug's patent does not expire until 2017, years after Lilly's top-selling creation, the antipsychotic drug Zyprexa, loses patent exclusivity, in 2011.

Yet Lilly faces confront ahead. Erectile dysfunction still carries a certain dishonor. There are lot more cultures in the world that are particularly in Asia, are known for not talking openly about sexual relationships. And the situation is one of the few that a man diagnoses himself, rather than getting a doctor to bring to his attention.

So Lilly sees it's confront as educating people across numerous cultures that erectile dysfunction can and should be treated. In France, Lilly has been viewing television spots influencing men with erectile dysfunction to go to the doctor early in life, saying the state could be an indication of cardiovascular sickness.

In the United States, Lilly has spent hundreds of millions of dollars on television ads with a more unswerving message. Lilly plans to revolve out a marketing campaign later this year in Japan, where discussions of intimacy often are taboo.